Karyopharm Q3 revenue $36.0M, net loss $0.30/sh; FY guidance reaffirmed

Karyopharm Therapeutics Inc.

2023-Q3 EPS reported -$0.89 revenue$112,286,000

U.S. XPOVIO net product revenue $30.2M, down from $32.0M year-over-year due to PAP use and 340B discounts.
Net loss of $34.5M ($0.30/sh) improved from $36.3M ($0.45/sh) in Q3 2022; cash $209.2M as of Sept 30, 2023.
Full-year 2023 guidance held: total revenue $145-160M, XPOVIO net revenue $110-125M, non-GAAP opex $240-255M.
NCCN elevated XVd to preferred category 1 for lenalidomide-refractory multiple myeloma after 1-3 prior lines.
Entered clinical collaboration with BMS to evaluate mezigdomide + selinexor in R/R myeloma post T-cell therapies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Karyopharm Therapeutics Inc. reported the quarter ended September 30, 2023 results: revenue $36.0 million. Guidance reaffirmed.

Period: the quarter ended September 30, 2023
Revenue: $36.0 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue for the third quarter of 2023 was $36.0 million, compared to $36.1 million for the third quarter of 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-268840

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.